164 related articles for article (PubMed ID: 28443391)
1. Atazanavir sulfate + cobicistat for the treatment of HIV infection.
Antunes F
Expert Rev Anti Infect Ther; 2017 Jun; 15(6):569-576. PubMed ID: 28443391
[TBL] [Abstract][Full Text] [Related]
2. Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial.
Gallant J; Moyle G; Berenguer J; Shalit P; Cao H; Liu YP; Myers J; Rosenblatt L; Yang L; Szwarcberg J
Curr HIV Res; 2017; 15(3):216-224. PubMed ID: 27774892
[TBL] [Abstract][Full Text] [Related]
3. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
Gallant JE; Koenig E; Andrade-Villanueva J; Chetchotisakd P; DeJesus E; Antunes F; Arastéh K; Moyle G; Rizzardini G; Fehr J; Liu Y; Zhong L; Callebaut C; Szwarcberg J; Rhee MS; Cheng AK
J Infect Dis; 2013 Jul; 208(1):32-9. PubMed ID: 23532097
[TBL] [Abstract][Full Text] [Related]
4. Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients.
Biagi M; Badowski ME; Chiampas T; Young J; Patel M; Vaughn P
Int J STD AIDS; 2017 Jul; 28(8):766-772. PubMed ID: 27587601
[TBL] [Abstract][Full Text] [Related]
5. Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS.
Putcharoen O; Do T; Avihingsanon A; Ruxrungtham K
Drug Des Devel Ther; 2015; 9():5763-9. PubMed ID: 26566368
[TBL] [Abstract][Full Text] [Related]
6. Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infection.
Crutchley RD; Guduru RC; Cheng AM
HIV AIDS (Auckl); 2016; 8():47-65. PubMed ID: 27022304
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial in healthy subjects to assess the bioequivalence of an atazanavir/cobicistat fixed-dose combination tablet versus administration as separate agents.
Sevinsky H; Tao X; Wang R; Ravindran P; Sims K; Xu X; Jariwala N; Bertz R
Antivir Ther; 2015; 20(5):493-500. PubMed ID: 25361436
[TBL] [Abstract][Full Text] [Related]
8. Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
Squires KE; Young B; Dejesus E; Bellos N; Murphy D; Zhao HH; Patel LG; Ross LL; Wannamaker PG; Shaefer MS;
AIDS; 2010 Aug; 24(13):2019-27. PubMed ID: 20613461
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN Study.
Teófilo E; Rocha-Pereira N; Kuhlmann B; Antela A; Knechten H; Santos J; Jiménez-Expósito MJ;
HIV Clin Trials; 2016 Feb; 17(1):17-28. PubMed ID: 26899539
[TBL] [Abstract][Full Text] [Related]
10. Cobicistat-boosted protease inhibitors in HIV-infected patients with mild to moderate renal impairment.
McDonald CK; Martorell C; Ramgopal M; Laplante F; Fisher M; Post FA; Liu Y; Curley J; Abram ME; Custodio J; Graham H; Rhee MS; Szwarcberg J
HIV Clin Trials; 2014; 15(6):269-73. PubMed ID: 25433666
[TBL] [Abstract][Full Text] [Related]
11. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection.
Deeks ED
Drugs; 2014 Feb; 74(2):195-206. PubMed ID: 24343782
[TBL] [Abstract][Full Text] [Related]
12. Darunavir/cobicistat for the treatment of HIV-1: a new era for compact drugs with high genetic barrier to resistance.
Capetti A; Cossu MV; Rizzardini G
Expert Opin Pharmacother; 2015; 16(17):2689-702. PubMed ID: 26612518
[TBL] [Abstract][Full Text] [Related]
13. Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-naïve and -experienced United Kingdom patients in 2011.
Simpson KN; Baran RW; Collomb D; Beck EJ; Van de Steen O; Dietz B
J Med Econ; 2012; 15(4):796-806. PubMed ID: 22563716
[TBL] [Abstract][Full Text] [Related]
14. Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.
d'Ettorre G; Ceccarelli G; Zaccarelli M; Ascoli-Bartoli T; Bianchi L; Bellelli V; De Girolamo G; Serafino S; Giustini N; Mastroianni CM; Vullo V
Int J STD AIDS; 2016 Jul; 27(8):638-43. PubMed ID: 26068963
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients.
Moltó J; Estévez JA; Miranda C; Cedeño S; Clotet B; Valle M
Br J Clin Pharmacol; 2016 Dec; 82(6):1528-1538. PubMed ID: 27447851
[TBL] [Abstract][Full Text] [Related]
16. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results.
Kozal MJ; Lupo S; DeJesus E; Molina JM; McDonald C; Raffi F; Benetucci J; Mancini M; Yang R; Wirtz V; Percival L; Zhang J; Zhu L; Arikan D; Farajallah A; Nguyen BY; Leavitt R; McGrath D; Lataillade M; The Spartan Study Team
HIV Clin Trials; 2012; 13(3):119-30. PubMed ID: 22592092
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients.
Gilliam BL; Chan-Tack KM; Qaqish RB; Rode RA; Fantry LE; Redfield RR
AIDS Patient Care STDS; 2006 Nov; 20(11):745-59. PubMed ID: 17134349
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF.
Harris M; Ganase B; Watson B; Hull MW; Guillemi SA; Zhang W; Saeedi R; Harrigan PR
HIV Clin Trials; 2017 Jan; 18(1):39-47. PubMed ID: 28067119
[TBL] [Abstract][Full Text] [Related]
19. Atazanavir/ritonavir: a review of its use in HIV therapy.
von Hentig N
Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
[TBL] [Abstract][Full Text] [Related]
20. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
Winston A; Mallon PW; Satchell C; MacRae K; Williams KM; Schutz M; Law M; Cooper DA; Emery S
Clin Infect Dis; 2007 Jun; 44(11):1475-83. PubMed ID: 17479946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
